5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity.
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer / Borro, Marina; Botticelli, Andrea; Mazzuca, Federica; Onesti, Elisa Concetta; Gentile, Giovanna; Romiti, Adriana; Cerbelli, Bruna; Mazzotti, Eva; Marchetti, Luca; Lionetto, Luana; Simmaco, Maurizio; Marchetti, Paolo. - In: ONCOTARGET. - ISSN 1949-2553. - STAMPA. - 8:(2016), pp. 14050-14057. [10.18632/oncotarget.12571]
Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer
BORRO, Marina;BOTTICELLI, ANDREA;MAZZUCA, FEDERICA;GENTILE, Giovanna;ROMITI, ADRIANA;CERBELLI, BRUNA;Mazzotti, Eva;SIMMACO, Maurizio;MARCHETTI, PAOLO
2016
Abstract
5-fluorouracil (5-FU) based chemotherapy is the most common first line regimen used in gastric and gastroesophageal junction cancer, but development of severe toxicity is a main concern in the treatment. The present study is aimed to evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), as a predictive factor for 5-FU toxicity.| File | Dimensione | Formato | |
|---|---|---|---|
|
in gastroesophageal 5fu 2016.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
910.28 kB
Formato
Adobe PDF
|
910.28 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
